Prof. Kristi Anseth – University of Colorado Boulder
Dr. Anseth is a Distinguished Professor, Tisone Professor of Chemical and Biological Engineering, and Head of Academic Leadership of the BioFrontiers Institute at the University of Colorado at Boulder. Her research interests lie at the interface between biology and engineering where she designs new biomaterials for applications in drug delivery and regenerative medicine. Dr. Anseth is an elected member of the National Academy of Engineering (2009), the National Academy of Medicine (2009), the National Academy of Sciences (2013), and the National Academy of Inventors (2016). She is also a Fellow of the American Association for the Advancement of Science, the American Institute for Medical and Biological Engineering, American Institute of Chemical Engineers, and the Materials Research Society. Dr. Anseth currently serves on the Board of Directors of the American Institute of Chemical Engineers, Board of Trustees for the Gordon Research Conferences, on the Scientific Advisory Board of the Allen Institute, and is an editor for Biomacromolecules and Progress in Materials Science.
Dr. Peter Green – National Renewable Energy Laboratory (NREL)
Dr. Green is the deputy laboratory director for Science and Technology and the chief research officer for NREL. Dr. Green is responsible for NREL’s science and research goals, strengthening the laboratory’s core capabilities, and enhancing NREL’s research portfolio. In addition, he oversees the Laboratory Directed Research and Development Program, NREL-university interactions, and the postdoctoral research program. Prior to his appointment at NREL, Dr. Green spent 20 years in academia (UT Austin and University of Michigan), and 11 years at Sandia National Laboratories. At University of Michigan, he served as chair of the Department of Materials Science and Engineering and the director of the Energy Department’s Energy Frontiers Research Center: Center for Solar and Thermal Energy Conversion. Dr. Green served as president of the Materials Research Society, and is fellow of American Physical Society, the American Ceramics Society, the Royal Society of Chemistry, and the American Association for the Advancement of Science.
Dr. Roger A. Hart – Amgen, Inc.
Dr. Roger Hart is a Scientific Director in the Drug Substance Technology Department within Process Development at Amgen. Prior to joining Amgen, Dr. Hart completed his Ph.D. research at the California Institute of Technology in Biochemical Engineering with a specialization in recovery of recombinant proteins. He then completed post-doctoral research at Genentech in the field of protein folding and liquid extraction; he subsequently joined the scientific staff at Genentech and contributed to development of some of Genentech’s earliest monoclonal antibody projects. Since joining Amgen almost twenty-five years ago, Dr. Hart has advanced the development of numerous protein, peptide, and monoclonal antibody products from the early therapeutic development stage through commercial licensure. Dr. Hart’s current responsibilities include identification, initiation, management, and cross-functional oversight of external strategic technology development initiatives with University and Industry Consortia to collaboratively advance emerging technologies for therapeutic development and manufacturing; his great passion involves developing technology which can be used to advance the deep and ever changing product pipeline within the Biopharmaceutical field and is an author of numerous patents and publications in the field.